Methods for tracking outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
- Population selection
- Brescia COVID-19 Respiratory Severity Scale (BCRSS)
- Other concurrent therapies
- TCZ dosage
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Outcomes among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Patient characteristics among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Laboratory findings among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Methods for tracking outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Discussion from "Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy"
Learn After
Brescia COVID-19 Respiratory Severity Scale (BCRSS)
Tocilizumab (TCZ) infusion dosage for study of outcomes among 100 severe COVID-19 patients in Brescia, Italy
Other concurrent therapies in evaluating outcomes among 100 severe COVID-19 patients in Brescia, Italy after Tocilizumab (TCZ) infusion
Population selection to track outcomes among 100 severe COVID-19 patients in Brescia, Italy after Tocilizumab (TCZ) infusion